It is estimated that 2% to 3% of the population are currently prescribed systemic or topical
glucocorticoid treatment. The potent anti-inflammatory action of glucocorticoids to deliver …

The understanding of idiopathic intracranial hypertension (IIH) has evolved over the past few
years. Previously, IIH was considered a disease exclusively affecting the neuro-ophthalmic …

Therapeutics to reduce intracranial pressure are an unmet need. Preclinical data have
demonstrated a novel strategy to lower intracranial pressure using glucagon-like peptide-1 …

Background There are limited longitudinal data evaluating outcomes in idiopathic
intracranial hypertension (IIH). We aimed to evaluate the long-term outcomes in a real-world …

Idiopathic intracranial hypertension (IIH) is characterized by increased intracranial pressure,
manifested by papilledema and radiological findings, in the absence of an identifiable …

Importance There is an unmet need for noninvasive biomarkers of intracranial pressure
(ICP), which manifests as papilledema that can be quantified by optical coherence …

Glucocorticoids prescribed to limit inflammation, have significant adverse effects. As 11β-
hydroxysteroid dehydrogenase type 1 (11β-HSD1) regenerates active glucocorticoid, we …

Objective Headache is a near‐universal sequela of idiopathic intracranial hypertension (IIH).
The aim of this paper is to report current knowledge of headache in IIH and to identify …

With increasing incidence and prevalence of Idiopathic intracranial hypertension in the UK,
the aim of this study was to explore emerging themes in Idiopathic intracranial hypertension …

Background The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
determines prereceptor metabolism and activation of glucocorticoids within peripheral …